Regen BioPharma, Inc. has engaged Charles River Laboratories to initiate a Good Laboratory Practices (GLP) toxicity study related to HemaXellerate, Regen’s cellular drug designed to heal damaged bone marrow.   Regen BioPharma has developed a protocol, which was reviewed by the FDA, for assessing safety of the HemaXellerate product in mice lacking an immune system. This sophisticated animal model is commonly used in cell therapy research as a last safety assessment before products enter clinical ...